Law Enforcement Track, National Rx Drug Abuse Summit, April 2-4, 2013. Building Public Safety and Public Health Partnerships to Reduce Prescription Drug Abuse presentation by Laurence Busching, Dr. Denise Paone and Dr. Jessica Kattan.
The document discusses new models of care needed due to increasing healthcare demands from an aging population and constrained resources. It notes rising medical card usage and healthcare costs for older groups. While primary care doctors make up a smaller portion of physicians compared to other countries, larger primary care centers in the future could provide selected procedures with sufficient volumes more efficiently than hospitals. The "sweet spot" is described as having strong clinical leadership, better patient experience, and more efficient resource use through approaches like increased scale and multi-disciplinary teams in primary care settings.
This document summarizes an approach called Agentic Health that provides population health assessment and engagement services. It trains Care Partners to conduct comprehensive health assessments and engage patients. The approach includes pre-populating assessments with existing data, producing reports for patients, providers and employers, and aggregating data to support quality improvement. Economics show the approach can be cost-effective with contributions over 17% at scale. The document outlines a consultation approach to help organizations pilot and implement the services.
Education Track, National Rx Drug Abuse Summit, April 2-4, 2013. Trends in Rx Drug Abuse presentation by Dr. Andrew Kolodny, Tess Benham and Sherry Green
This document outlines strategies for addressing the heroin epidemic at the community level. It discusses the Overdose Suppression Project led by Detective Gary Martin which uses a comprehensive approach including law enforcement, public awareness, and quantitative research. Non-profit organizations NOPE Task Force and Heroin Awareness Committee are also discussed and their approaches to community partnerships, education, family support, and advocacy. The presentation aims to provide guidance on developing successful community strategies to reduce overdose deaths.
Treatment Track, National Rx Drug Abuse Summit, April 2-4, 2013. Treatment Options for Juveniles
presentation by Michelle Lipinski and Dr. Marc Fishman.
Treatment Track, National Rx Drug Abuse Summit, April 2-4, 2013. A Comprehensive Response to the Opioid Crisis presentation by Dr. Marvin Seppala, Scott Hesseltine and Fred Holmquist
The document discusses new models of care needed due to increasing healthcare demands from an aging population and constrained resources. It notes rising medical card usage and healthcare costs for older groups. While primary care doctors make up a smaller portion of physicians compared to other countries, larger primary care centers in the future could provide selected procedures with sufficient volumes more efficiently than hospitals. The "sweet spot" is described as having strong clinical leadership, better patient experience, and more efficient resource use through approaches like increased scale and multi-disciplinary teams in primary care settings.
This document summarizes an approach called Agentic Health that provides population health assessment and engagement services. It trains Care Partners to conduct comprehensive health assessments and engage patients. The approach includes pre-populating assessments with existing data, producing reports for patients, providers and employers, and aggregating data to support quality improvement. Economics show the approach can be cost-effective with contributions over 17% at scale. The document outlines a consultation approach to help organizations pilot and implement the services.
Education Track, National Rx Drug Abuse Summit, April 2-4, 2013. Trends in Rx Drug Abuse presentation by Dr. Andrew Kolodny, Tess Benham and Sherry Green
This document outlines strategies for addressing the heroin epidemic at the community level. It discusses the Overdose Suppression Project led by Detective Gary Martin which uses a comprehensive approach including law enforcement, public awareness, and quantitative research. Non-profit organizations NOPE Task Force and Heroin Awareness Committee are also discussed and their approaches to community partnerships, education, family support, and advocacy. The presentation aims to provide guidance on developing successful community strategies to reduce overdose deaths.
Treatment Track, National Rx Drug Abuse Summit, April 2-4, 2013. Treatment Options for Juveniles
presentation by Michelle Lipinski and Dr. Marc Fishman.
Treatment Track, National Rx Drug Abuse Summit, April 2-4, 2013. A Comprehensive Response to the Opioid Crisis presentation by Dr. Marvin Seppala, Scott Hesseltine and Fred Holmquist
This document summarizes a panel discussion on trends in prescribing practices. The panel included experts from the CDC and pharmacy who discussed current trends in prescribing controlled substances and best practices for utilizing prescription drug monitoring programs. They also evaluated opportunities for pharmacists to collaborate with prescribers to create effective treatment plans for patients.
This document discusses the growing problem of prescription drug abuse and misuse in the United States. It summarizes recent trends showing increasing rates of prescription drug misuse and overdose deaths. It outlines how commonly abused drug classes like opioids and stimulants affect the brain and explains why people abuse these drugs for their rewarding effects. It also describes strategies being developed to increase treatment, such as new medications to treat addiction and reverse overdoses, as well as health applications and interventions to address this important public health issue.
This document outlines an opioid abuse prevention plan 2.0. It summarizes data showing increasing opioid and heroin overdose deaths between 1999-2013. It discusses efforts to increase prescriber education, expand prescription drug monitoring programs, improve drug disposal, and make naloxone more available. The plan focuses on continued education, monitoring, disposal, enforcement, and expanding treatment and overdose prevention programs like medication-assisted treatment and naloxone access.
Three key points emerged from the document:
1) Patient advocacy groups and unions see the choice of drug as a matter between doctors and patients, and do not want employers, governments, or others interfering in drug decisions.
2) Both patient groups and unions want new drugs and devices to be publicly funded, believing they are safer and more effective, though cost is a major concern for Pharmacare plans and employers.
3) Unions and their members generally support the idea of national Pharmacare but more education is needed to help members understand and support evidence-based managed formularies being negotiated by employers.
The document discusses the issue of prescription drug abuse in the United States. It provides statistics showing the dramatic rise in prescription opioids dispensed between 2000-2009, as well as related increases in overdose deaths, emergency department visits, and deaths exceeding other causes like firearms or car accidents. The White House Office of National Drug Control Policy has developed a Prescription Drug Abuse Prevention Plan with four key areas of focus: education for healthcare providers, improving prescription drug monitoring programs, secure medication disposal, and enforcement efforts. The goal is a coordinated federal response to address this public health crisis.
This document discusses drug education and prevention in England. It provides statistics on alcohol deaths among youth and government spending on drug education, which has decreased. Surveys found that many students do not remember receiving drug education and that it is not a priority in schools. Evidence shows that early intervention programs between ages 6-15 that teach life skills can significantly reduce substance use. However, scare tactics and programs led by police are not effective. The document advocates following evidence-based programs and ensuring local leadership prioritizes effective drug education.
National Rx Drug Abuse Summit, April 2-4, 2013, General Session presentation "Realities of Addiction," by Dr. Nora Volkow, Director, National Institute on Drug Abuse
The document summarizes research analyzing associations between opioid overdose rates and rates of questionable prescription activity in Massachusetts communities. Key findings include:
1. Rates of opioid overdoses were positively associated with population density, poverty rates, and rates of questionable prescription activity in communities after controlling for other socioeconomic factors.
2. Rates of questionable prescription activity predicted subsequent increases in opioid overdose rates in communities over time, even after accounting for initial overdose rates and socioeconomic characteristics.
3. This research provides some of the first evidence that prescription drug monitoring program measures of questionable activity are useful indicators of geographic areas facing higher risks of opioid overdose.
This document discusses responsible opioid prescribing practices and strategies to lower opioid overdose deaths while maintaining appropriate treatment of chronic pain. It outlines learning objectives around cautious, evidence-based prescribing and identifying best practice strategies for pain management. It also explains evidence-based practices and policies for provider and patient education programs being used in the US.
Cleveland Plus March 2009 Quarterly Economic ReviewTeam NEO
The document discusses how the biomedical industry is a growing sector in Northeast Ohio, fueled by billions in investments, research funding, and partnerships between universities, hospitals, and businesses. It highlights that the regional biomedical industry has grown over 30% in the past 5 years and now includes over 600 companies. Furthermore, sectors like medical devices and equipment manufacturing have increased by 75% in the past 5 years, showing the transition of the regional economy.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
This document discusses the role of health departments in preventing neonatal abstinence syndrome (NAS). It notes that NAS rates have increased significantly in recent years, disproportionately affecting women. Health departments engage in surveillance to monitor NAS trends, partner with other organizations, support treatment and recovery programs, and provide education to prevent NAS, which is entirely preventable. The document outlines specific strategies health departments use across these areas to address the opioid epidemic and protect maternal and infant health.
The document discusses the opioid crisis in the United States, including rising rates of prescription opioid misuse and abuse, as well as heroin use and overdose deaths. It outlines how research can help address this crisis through developing less abusable analgesics, expanding access to treatment medications like naloxone and buprenorphine, and exploring new treatment approaches such as immunotherapies and precision medicine targeting genetic factors. The National Institute on Drug Abuse is supporting these research efforts and working to disseminate findings to improve prevention and intervention programs.
This document summarizes the opioid crisis in the United States from 2000 to 2014. It shows that the number of opioid-related overdose deaths more than tripled during this period, increasing from about 8,000 to over 28,000. Additionally, 7.9 million Americans aged 12 or older met the criteria for an illicit drug use disorder in 2013-2014 but only 20% received treatment. The document outlines actions by the Obama administration to address the crisis and increase funding for treatment. It emphasizes that stories can help reduce stigma and that recovery is possible through working together.
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
This presentation covered multi-media prevention strategies for issues like prescription drug overdoses. It discussed the CDC's digital Rx drug prevention campaign, best practices for digital messaging, and programs using expectancy challenge theory and media literacy education in schools. Presenters included representatives from the CDC, Media Literacy for Prevention, and the Hanley Center Foundation who discussed their work developing and implementing digital communications and single-session prevention programs.
More Related Content
Similar to Building public safety_public_health_partnerships_final
This document summarizes a panel discussion on trends in prescribing practices. The panel included experts from the CDC and pharmacy who discussed current trends in prescribing controlled substances and best practices for utilizing prescription drug monitoring programs. They also evaluated opportunities for pharmacists to collaborate with prescribers to create effective treatment plans for patients.
This document discusses the growing problem of prescription drug abuse and misuse in the United States. It summarizes recent trends showing increasing rates of prescription drug misuse and overdose deaths. It outlines how commonly abused drug classes like opioids and stimulants affect the brain and explains why people abuse these drugs for their rewarding effects. It also describes strategies being developed to increase treatment, such as new medications to treat addiction and reverse overdoses, as well as health applications and interventions to address this important public health issue.
This document outlines an opioid abuse prevention plan 2.0. It summarizes data showing increasing opioid and heroin overdose deaths between 1999-2013. It discusses efforts to increase prescriber education, expand prescription drug monitoring programs, improve drug disposal, and make naloxone more available. The plan focuses on continued education, monitoring, disposal, enforcement, and expanding treatment and overdose prevention programs like medication-assisted treatment and naloxone access.
Three key points emerged from the document:
1) Patient advocacy groups and unions see the choice of drug as a matter between doctors and patients, and do not want employers, governments, or others interfering in drug decisions.
2) Both patient groups and unions want new drugs and devices to be publicly funded, believing they are safer and more effective, though cost is a major concern for Pharmacare plans and employers.
3) Unions and their members generally support the idea of national Pharmacare but more education is needed to help members understand and support evidence-based managed formularies being negotiated by employers.
The document discusses the issue of prescription drug abuse in the United States. It provides statistics showing the dramatic rise in prescription opioids dispensed between 2000-2009, as well as related increases in overdose deaths, emergency department visits, and deaths exceeding other causes like firearms or car accidents. The White House Office of National Drug Control Policy has developed a Prescription Drug Abuse Prevention Plan with four key areas of focus: education for healthcare providers, improving prescription drug monitoring programs, secure medication disposal, and enforcement efforts. The goal is a coordinated federal response to address this public health crisis.
This document discusses drug education and prevention in England. It provides statistics on alcohol deaths among youth and government spending on drug education, which has decreased. Surveys found that many students do not remember receiving drug education and that it is not a priority in schools. Evidence shows that early intervention programs between ages 6-15 that teach life skills can significantly reduce substance use. However, scare tactics and programs led by police are not effective. The document advocates following evidence-based programs and ensuring local leadership prioritizes effective drug education.
National Rx Drug Abuse Summit, April 2-4, 2013, General Session presentation "Realities of Addiction," by Dr. Nora Volkow, Director, National Institute on Drug Abuse
The document summarizes research analyzing associations between opioid overdose rates and rates of questionable prescription activity in Massachusetts communities. Key findings include:
1. Rates of opioid overdoses were positively associated with population density, poverty rates, and rates of questionable prescription activity in communities after controlling for other socioeconomic factors.
2. Rates of questionable prescription activity predicted subsequent increases in opioid overdose rates in communities over time, even after accounting for initial overdose rates and socioeconomic characteristics.
3. This research provides some of the first evidence that prescription drug monitoring program measures of questionable activity are useful indicators of geographic areas facing higher risks of opioid overdose.
This document discusses responsible opioid prescribing practices and strategies to lower opioid overdose deaths while maintaining appropriate treatment of chronic pain. It outlines learning objectives around cautious, evidence-based prescribing and identifying best practice strategies for pain management. It also explains evidence-based practices and policies for provider and patient education programs being used in the US.
Cleveland Plus March 2009 Quarterly Economic ReviewTeam NEO
The document discusses how the biomedical industry is a growing sector in Northeast Ohio, fueled by billions in investments, research funding, and partnerships between universities, hospitals, and businesses. It highlights that the regional biomedical industry has grown over 30% in the past 5 years and now includes over 600 companies. Furthermore, sectors like medical devices and equipment manufacturing have increased by 75% in the past 5 years, showing the transition of the regional economy.
Similar to Building public safety_public_health_partnerships_final (13)
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
This document discusses the role of health departments in preventing neonatal abstinence syndrome (NAS). It notes that NAS rates have increased significantly in recent years, disproportionately affecting women. Health departments engage in surveillance to monitor NAS trends, partner with other organizations, support treatment and recovery programs, and provide education to prevent NAS, which is entirely preventable. The document outlines specific strategies health departments use across these areas to address the opioid epidemic and protect maternal and infant health.
The document discusses the opioid crisis in the United States, including rising rates of prescription opioid misuse and abuse, as well as heroin use and overdose deaths. It outlines how research can help address this crisis through developing less abusable analgesics, expanding access to treatment medications like naloxone and buprenorphine, and exploring new treatment approaches such as immunotherapies and precision medicine targeting genetic factors. The National Institute on Drug Abuse is supporting these research efforts and working to disseminate findings to improve prevention and intervention programs.
This document summarizes the opioid crisis in the United States from 2000 to 2014. It shows that the number of opioid-related overdose deaths more than tripled during this period, increasing from about 8,000 to over 28,000. Additionally, 7.9 million Americans aged 12 or older met the criteria for an illicit drug use disorder in 2013-2014 but only 20% received treatment. The document outlines actions by the Obama administration to address the crisis and increase funding for treatment. It emphasizes that stories can help reduce stigma and that recovery is possible through working together.
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
This presentation covered multi-media prevention strategies for issues like prescription drug overdoses. It discussed the CDC's digital Rx drug prevention campaign, best practices for digital messaging, and programs using expectancy challenge theory and media literacy education in schools. Presenters included representatives from the CDC, Media Literacy for Prevention, and the Hanley Center Foundation who discussed their work developing and implementing digital communications and single-session prevention programs.
This document discusses strategies for reducing buprenorphine diversion and pill mills while improving access to treatment. It notes that limiting access to buprenorphine treatment is associated with increased diversion, while expanded access to quality treatment decreases diversion and overdose deaths. The document recommends educating prescribers, using medically-derived prescribing standards, ensuring adequate insurance coverage of safe prescribing practices, and addressing diversion risks for other controlled medications. It argues against onerous new regulations that could limit treatment access. The goal is to identify and support high-quality treatment while prosecuting criminal operations.
This document summarizes a presentation on linking and mapping prescription drug monitoring program (PDMP) data. It discusses the benefits of linking PDMP data to clinical data, including improving patient safety, evaluating prescribing decisions, and assessing the impact of PDMP interventions. It describes challenges with linking data, such as obtaining consent and negotiating data use agreements. It also discusses Washington State's MAPPING OPIOID AND OTHER DRUG ISSUES (MOODI) tool, which integrates PDMP data with other databases to map and target treatment and overdose prevention efforts at the community level.
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
This document discusses workplace issues related to prescription drug abuse and strategies for prevention. It begins with introductions of the presenters and moderators. The learning objectives are then outlined as understanding challenges of prescription drug abuse in the workplace, identifying prevention strategies, and describing programs available through SAMHSA. The document then covers topics such as the scope of prescription drug misuse among workers, risks to the workplace, prevention strategies employers can consider, and available resources from SAMHSA.
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
This document discusses a presentation on pharmacy burglary, robbery, and diversion of prescription drugs. The presentation covers trends in prescription drug diversion, particularly those involving robbery and burglary of pharmacies. It identifies preventative measures to enhance pharmacy security and safety. Strategies to reduce pharmacy crimes are outlined. The offender perspective is examined based on interviews with convicted offenders. Routine activities theory is discussed as relating to suitable targets, capable guardians, and motivated offenders. Partnerships between regulatory agencies and law enforcement are emphasized as key to prevention efforts.
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
This document summarizes presentations from two communities - Huntington, WV and Camden County, NJ - on their responses to heroin crises. It outlines programs implemented in Huntington, including a harm reduction program, centralized information system, and drug court expansion. It also discusses the region's history with prescription drug abuse and rise in heroin and associated issues like hepatitis and neonatal abstinence syndrome. Long-term strategies proposed include expanding treatment services, promoting career opportunities for those in recovery, and preventing relapse through environmental design changes.
This document discusses neonatal abstinence syndrome (NAS) and universal maternal drug testing. It provides background information on NAS including trends showing large increases in incidence and costs associated with NAS. It outlines objectives related to describing NAS trends, identifying legislative activities impacting NAS, describing family planning for women in substance abuse treatment, and explaining a hospital program using universal drug testing. The document then covers topics including NAS symptoms, incidence and geographic trends, costs of NAS, opioid use in women of childbearing age, unintended pregnancy rates, contraceptive use among opioid users, and maternal drug exposure sources.
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
This document outlines an advocacy track presentation on activating communities to address prescription drug abuse. It provides biographies of the presenters and moderators and discloses any conflicts of interest. The learning objectives are to identify best practices for implementing CADCA's seven strategies for community change to impact prescription drug issues. It then provides examples of how various coalitions across the country are utilizing each of the seven strategies, such as providing education, enhancing skills, supporting communities, and changing policies.
This document discusses recovery ready ecosystems and recovery community organizations. It introduces presenters from Young People in Recovery and Hope House Treatment Track who will discuss interventions, prevention, and recovery programs. Examples of Young People in Recovery chapters, programs, and services are provided, including employment workshops, education workshops, housing workshops, and recovery support services. The document also discusses recovery community organizations and initiatives in Texas and Georgia, such as the Association of Persons Affected by Addiction in Dallas and the Georgia Council on Substance Abuse.
This document summarizes a presentation on health plan involvement in safe prescribing. It includes:
1) Presentations from medical experts on prescription drug abuse trends from medical examiner data and a tribal health system's safe prescribing program.
2) A discussion of health plan policies to reduce "red flag" medication combinations like opioids plus benzodiazepines through prior authorization, formulary changes, and provider restrictions.
3) Examples of one health plan's implementation of policies like restricting methadone prescriptions to pain specialists and removing carisoprodol from its formulary.
Building public safety_public_health_partnerships_final
1. Building
Public
Safety
and
Public
Health
Partnerships
to
Reduce
Prescrip9on
Drug
Abuse
Laurence
Busching
First
Deputy
Criminal
Jus2ce
Coordinator,
City
of
New
York
Denise
Paone
Director
of
Research
and
Surveillance,
Bureau
of
Alcohol
and
Drug
Use
Preven2on,
Care
and
Treatment,
New
York
City
Department
of
Health
and
Mental
Hygiene
Dr.
Jessica
Ka@an
CDC
Health
Systems
Integra2on
Program
Scholar,
Centers
for
Disease
Control
and
Preven2on,
SciMetrika
Contractor,
Assigned
to
New
York
City
Department
of
Health
and
Mental
Hygiene.
2. How
To
Work
with
Public
Health
Data
in
Inves9ga9ons
April
2
–
4,
2013
Omni
Orlando
Resort
at
ChampionsGate
3. Learning
Objec9ves
• Outline
strategies
to
create
alliances
across
agency
lines.
• Explain
how
to
leverage
public
health
data
in
inves2ga2ons.
• Outline
the
importance
of
collabora2on
between
public
health
officials
and
law
enforcement
in
inves2ga2ons.
3
4. Disclosure
Statement
Laurence
Busching,
Dr.
Jessica
KaXan,
Dr.
Denise
Paone,
Chauncey
Parker,
and
Edward
Carrasco
have
no
financial
rela2onships
with
proprietary
en22es
that
produce
health
care
goods
and
services.
4
5. Outline
• The
Threat
in
New
York
City
(Dr.
Denise
Paone,
NYC
DOHMH)
• Mayor’s
Task
Force
on
Prescrip9on
Painkiller
Abuse
(Laurence
Busching,
New
York
City’s
Mayor’s
Office)
• Public
Health/Public
Safety
Ini9a9ves
– RxStat
(Dr.
Denise
Paone,
NYC
DOHMH)
– Prescribing
Guidelines
(Dr.
Jessica
KaCan,
NYC
DOHMH)
– Public
Safety
(Chauncey
Parker,
NY/NJ
HIDTA)
– NYPD
Ini9a9ves
(Edward
Carrasco,
NYPD)
• Public
Health/Public
Safety
Partnerships
5
6. Dr.
Denise
Paone,
Director
of
Research
and
Surveillance
New
York
City
Department
of
Health
and
Mental
Hygiene
THE
THREAT
IN
NEW
YORK
CITY
7. Opioid
analgesic
misuse
and
the
associated
consequences
have
led
to
a
public
health
crisis
in
New
York
City.
7
8. • From
2005-‐2011,
the
rate
of
opioid
analgesic
overdose
deaths
increased
65%,
heroin
overdose
deaths
decreased
8%.
• In
2011,
more
than
one
fatal
opioid
analgesic
overdose
occurred
every
other
day
in
New
York
City.
• In
2005,
opioid
analgesics
were
involved
in
16%
of
overdose
deaths;
in
2011,
they
were
involved
in
35%.
8
9. Exis9ng
Data/Surveillance
on
Opioid
Analgesic
(Pain
Reliever)
Misuse
Overdose
Mortality
Death
Cer2ficates
deaths?
Health
ED
Visits,
Treatment
Morbidity
Admissions
consequences?
Prescrip2ons
Prescribing
PDMP
Data
Filled?
How
Many
Na2onal
Survey
on
Prevalence
Drug
User
Health
Users?
9
10. Overdose
Deaths
Decreased
22%
in
NYC
500
Cocaine
Heroin
Methadone
400
Benzodiazepines
Opioid
Analgesics
300
Number
200
100
Drugs
are
not
mutually
exclusive
0
2005
2006
2007
2008
2009
2010
2011
Year
Source: New York City Office of the Chief Medical Examiner &
New York City Department of Health and Mental Hygiene 2005-2011
10
11. Opioid
analgesic
overdose
deaths
increased
65%
250
4.0
Opioid
analgesic
overdose
deaths,
NYC,
2005-‐2011
3.3
3.5
200
3.0
2.6
2.4
Age-‐Adjusted
Rate
per
100,000
2.3
2.5
150
2.0
2.0
2.0
2.0
Number
100
1.5
1.0
50
0.5
130
152
131
137
158
173
220
0
0.0
2005
2006
2007
2008
2009
2010
2011
Number
of
opioid
analgesic
overdose
deaths
Age-‐adjusted
opioid
analgesic
rates
per
100,000
popula9on
Source: New York City Office of the Chief Medical Examiner &
New York City Department of Health and Mental Hygiene 2005-2011
11
12. Opioid
Analgesic-‐related
Emergency
Department
Visit
Rates
Doubled
from
2004
to
2010
Opioid
analgesic
misuse/abuse
emergency
department
visits,
12,000
NYC
2004-‐2010
129.2
140.0
113.1
110.3
120.0
Age-‐adjusted
rate
per
100,000
10,000
103.2
89.8
100.0
8,000
79.8
Number
80.0
6,000
54.7
10,843
60.0
9,442
9,254
4,000
8,577
7,411
40.0
6,560
2,000
4,466
20.0
0
0.0
2004
2005
2006
2007
2008
2009
2010
Number
of
opioid
analgesics
ED
visits
Source: Drug Abuse Warning Network, Center for Behavioral Health Statistics and
Quality, Substance Abuse Mental Health Services Administration, 2004-2010
12
13. Oxycodone
prescrip9ons
increased
51%
from
2008
to
2010
in
NYC
2,500,000
2,000,000
All
prescrip9ons
prescrip9ons
Number
of
1,500,000
Oxycodone
1,000,000
Hydrocodone
500,000
2008
2009
2010
Year
Dispensed
Source: New York State Department of Health, Bureau of Narcotic
Enforcement, Prescription Drug Monitoring Program, 2008-2010 13
14. 15%
of
prescribers
write
82%
of
opioid
analgesic
prescrip9ons
Prescrip2ons
filled
by
NYC
residents,
2010
100% 1%
90% 15%
14%
Very Frequent
Prescribers
31%
530-10,185 RX/year
80%
70% Frequent
36% Prescribers
60% 50-529 RX/year 82%
Percent
50% Occasional
Prescribers 51%
40%
4-49 RX/year
30%
49% Rare Prescribers
20% 1-3 RX/year
10% 15%
0% 2%
Prescribers Prescriptions
Prescribing frequency
Source: New York State Department of Health, Bureau of Narcotic
Enforcement, Prescription Drug Monitoring Program, 2008-2010 14
15. Neighborhoods
with
Highest
Rates
of
Opioid
Prescrip9ons
have
Highest
Rates
of
Overdose
Deaths
Rates
of
prescrip9ons
filled
for
opioid
Rates
of
uninten9onal
opioid
analgesics
by
NYC
neighborhood
analgesic
overdose
deaths
by
NYC
neighborhood
Source: New York State Department of Health, Bureau of Narcotic
Enforcement, Prescription Drug Monitoring Program, 2008-2009;
New York City Office of the Chief Medical Examiner &New York City
Department of Health and Mental Hygiene 2008-2009 15
16. Most
Commonly
Used
Drugs
Are
Opioid
Analgesics
5%
Self-‐reported
drug
use
in
past
12
months,
NYC,
aged
12+
Opioid
Analgesics
4%
3%
Cocaine
Percent
2%
Benzodiazepines
1%
Heroin
0%
2002-‐03
2004-‐05
2006-‐07
2008-‐09
2010-‐11
Self-‐reported
year
of
use
(two
year
average)
Source: Substance Abuse Mental Health Services Administration, Office of
Applied Studies, 2002-2009 National Surveys on Drug Use and Health 16
17. Laurence
Busching,
First
Deputy
Criminal
Jus2ce
Coordinator
New
York
City
Office
of
the
Mayor
NYC
MAYOR’S
TASK
FORCE
ON
PRESCRIPTION
PAINKILLER
ABUSE
18. NYC
Mayor’s
Task
Force
on
Prescrip9on
Painkiller
Abuse
Co-‐chair,
Criminal
Jus2ce
Coordinator
Co-‐chair,
Deputy
Mayor
for
Health
and
Human
Services
New
York
City
Department
of
Health
and
Mental
Hygiene
New
York
City
Police
Department
New
York
City
Department
of
Educa2on
Health
and
Hospitals
Corpora2on
Human
Resources
Administra2on
Mayor’s
Office
of
Policy
and
Strategic
Planning
Richmond
County
District
AXorney’s
Office
Office
of
the
Special
Narco2cs
Prosecutor
Drug
Enforcement
Administra2on
NY/NJ
HIDTA
18
19. Task
Force
Work
Groups
• Data
• Legisla9on
• Preven9on
and
Treatment
• Law
Enforcement
19
20. Dr.
Denise
Paone,
Director
of
Research
and
Surveillance
New
York
City
Department
of
Health
and
Mental
Hygiene
RXSTAT:
NYC’S
COMPREHENSIVE
DRUG
SURVEILLANCE
SYSTEM
“COMPSTAT
for
PrescripNon
Drug
Abuse”
21. RxStat
Goals
“COMPSTAT
for
PrescripNon
Drug
Abuse”
Reduce
prescrip+on
drug
misuse
in
NYC
and
associated
health
and
safety
consequences
by:
• Facilita2ng
accurate
and
2mely
analysis
of
public
health
and
public
safety
data.
• Targe2ng
resources
and
coordina2ng
efforts
to
provide
the
most
effec2ve
and
efficient
City
response.
• Providing
measures
to
track
strategies.
21
22. RxStat
“COMPSTAT
for
PrescripNon
Drug
Abuse”
• Public
Health
&
Public
Safety
Collabora2on.
• “Real-‐2me”
(enhanced)
surveillance.
• Par2cipants
and
stakeholders
at
city,
state,
and
federal
organiza2ons.
• Monthly
RxStat
mee2ngs
with
key
stakeholders.
22
23. Enhanced
Surveillance
Efforts
Monthly
Monitoring,
OCME
BoXle
Mortality
Project*
Daily
ED
Visits,
Daily
NYC
PCC
Calls,
Morbidity
Quarterly
Treatment
Admissions
Quarterly
PDMP
data,
Quarterly
Prescribing
DEA
Data
Prevalence
&
Qualita2ve
Component,
Data
Intelligence
Analy2cs/Mapping
Crime
&
Monthly
Prosecu2ons*,
NYPD
Data,
Diversion
Quarterly
DEA
Losses,
Rx
Crimes*
*Discussed
in
more
detail
later
in
the
presentaNon.
23
24. RxStat
“COMPSTAT
for
PrescripNon
Drug
Abuse”
RxStat
creates
a
plaqorm
for
collabora2ve
problem
solving
to
reduce
prescrip2on
drug
abuse.
24
25. Dr.
Jessica
KaXan,
CDC
Health
Systems
Integra2on
Program
Scholar
Centers
for
Disease
Control
and
Preven2on,
SciMetrika
Contractor
Assigned
to
New
York
City
Department
of
Health
and
Mental
Hygiene
BEST
PRACTICES
PRESCRIBING
GUIDELINES
27. Emergency
Department
Opioid
Prescribing
Guidelines:
Goal
and
Ra9onale
• Establish
standards
for
prescribing.
• Balance
pain
treatment
with
reducing
opioid
analgesic
misuse.
• Why
Emergency
Departments?
– Pain
is
a
common
presenta2on
in
EDs.
– Opioid
analgesics
are
commonly
prescribed
in
EDs,
although
EDs
not
the
main
source.
– One
component
of
a
mul2-‐pronged
approach.
27
28. Target
&
Adop9on
• Pa2ents
discharged
from
EDs.
• Not
meant
for
pallia2ve
care
programs
or
cancer
pain.
• Adopted
by
all
Health
and
Hospitals
Corpora2on
EDs
(NYC’s
public
hospital
system).
28
31. Chauncey
Parker,
Director
New
York/New
Jersey
High
Intensity
Drug
Trafficking
Area
APPLICATION
IN
PUBLIC
SAFETY
&
RX
CRIMES
32. Overdose
Death
Prescrip9ons
• Office
of
the
Chief
Medical
Examiner
(OCME)
began
collec2ng
prescrip2on
boXles
at
death
scenes.
• Partnership
allowed
resources
to
log
the
boXle
informa2on.
• Data
in
process
of
being
compiled
as
poten2al
supplemental
intelligence.
32
33. New
York
County
2012
Drug
Prosecu9ons
by
Drug
Type
(reflec2ng
11,712
instances
of
drugs
in
10,559
prosecu2ons)
“Benzodiazepines”
includes
Alprazolam,
Clonazepam,
Diazepam,
etc.
“Opioid
Analgesics”
includes
pure
&
compound
versions
of
Oxycodone,
Hydrocodone,
Oxymorphone,
Morphine,
etc.
(excludes
Methadone).
33
34. Oxycodone
&
Oxycodone
Compounds
Arrest
Loca9ons
Reflec9ng
160
Prosecu9ons
in
Three
Upper
Manha@an
Precincts
34
35. Rx
Crimes
• Central
repository
for
Rx-‐related
Robberies/Burglaries,
direct
LEA
access
to
police
reports.
• Fill
cross-‐border/interagency
sharing
gap.
• Allow
proac2ve
analysis:
— Emerging
crime
paXerns
(e.g.,
through
the
roof)
— Security
alerts
— Sources
of
drugs
— Targeted
drugs
35
36. Edward
Carrasco,
Deputy
Inspector
Office
of
Management
Analysis
and
Planning
New
York
Police
Department
NEW
YORK
POLICE
DEPARTMENT
RX
DRUG
INITIATIVES
37. NYPD
Rx
Drug
Ini9a9ves
Emphasis
on
Community
Engagement
• Partnership
with
schools
• Pharmacy
Crimes
Reduc2on
Ini2a2ve
• Other
awareness
programs
37
38. Laurence
Busching,
First
Deputy
Criminal
Jus2ce
Coordinator
New
York
City
Office
of
the
Mayor
PUBLIC
HEALTH
&
PUBLIC
SAFETY
PARTNERSHIPS
39. Challenges
&
Conclusions
• Legality
of
prescrip2on
drugs
• Complexi2es
of
regula2on
• Data
availability/data
silos
• Terminology
across
fields
• Addressing
misinforma2on
• Developing
collabora2ve
approaches
Common
Goal
-‐
Reduce
prescrip+on
drug
abuse
and
the
associated
public
health
and
public
safety
consequences.
39
40. Ques9ons
For
more
informa2on
contact:
John
Hreno
-‐
jhreno@nynjhidta.org
40